Several other analysts have also recently commented on the stock. Analysts at Nomura (NYSE: NMR) initiated coverage on shares of Shire PLC in a research note to investors on Wednesday, April 4th. They set a “buy” rating on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Shire PLC in a research note to investors on Wednesday, April 4th. They set a “market perform” rating on the stock. Finally, analysts at Deutsche Bank (NYSE: DB) cut their price target on shares of Shire PLC from $116.00 to $105.00 in a research note to investors on Monday, April 2nd.
Shire PLC traded down 1.17% on Friday, hitting $97.17. Shire PLC has a 52-week low of $85.99 and a 52-week high of $108.79. The company has a market cap of $18.019 billion and a price-to-earnings ratio of 21.10.
Shire PLC last posted its quarterly earnings results on Thursday, April 26th. The company reported $1.24 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.52 by $0.72. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. On average, analysts predict that Shire PLC will post $1.52 earnings per share next quarter.
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.